About Fulcrum Therapeutics, Inc.
https://www.fulcrumtx.comFulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
CEO
Alexander C. Sapir
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 80
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Truist Securities
Buy
HC Wainwright & Co.
Buy
Leerink Partners
Outperform
Cantor Fitzgerald
Overweight
Piper Sandler
Overweight
RBC Capital
Sector Perform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:10.23M
Value:$105.97M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:5.38M
Value:$55.75M
TCG CROSSOVER MANAGEMENT, LLC
Shares:5.25M
Value:$54.39M
Summary
Showing Top 3 of 140
About Fulcrum Therapeutics, Inc.
https://www.fulcrumtx.comFulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $21.86M ▲ | $-19.59M ▼ | 0% | $-0.31 ▼ | $-19.25M ▼ |
| Q2-2025 | $0 | $19.52M ▼ | $-17.3M ▲ | 0% | $-0.28 | $-16.95M ▲ |
| Q1-2025 | $0 | $20.4M ▲ | $-17.66M ▼ | 0% | $-0.28 ▲ | $-20.05M ▼ |
| Q4-2024 | $0 | $19.06M ▼ | $-16.57M ▲ | 0% | $-0.31 ▲ | $-16.2M ▲ |
| Q3-2024 | $0 | $25.13M | $-21.7M | 0% | $-0.35 | $-22.69M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $200.65M ▼ | $214.86M ▼ | $16.49M ▲ | $198.37M ▼ |
| Q2-2025 | $214.11M ▼ | $228.84M ▼ | $14.46M ▲ | $214.38M ▼ |
| Q1-2025 | $226.6M ▼ | $242.65M ▼ | $14.16M ▼ | $228.49M ▼ |
| Q4-2024 | $241.02M ▼ | $260.72M ▼ | $17.68M ▼ | $243.03M ▼ |
| Q3-2024 | $257.23M | $279.01M | $21.72M | $257.29M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-19.59M ▼ | $-14.19M ▼ | $18.61M ▲ | $64K ▼ | $4.49M ▲ | $-14.28M ▼ |
| Q2-2025 | $-17.3M ▲ | $-13.82M ▲ | $13.93M ▲ | $301K ▲ | $414K ▲ | $-13.88M ▲ |
| Q1-2025 | $-17.66M ▼ | $-15.26M ▲ | $-777K ▼ | $0 ▼ | $-16.03M ▼ | $-15.26M ▲ |
| Q4-2024 | $-16.57M ▲ | $-16.76M ▲ | $2.26M ▼ | $83K ▼ | $-14.42M ▼ | $-16.99M ▲ |
| Q3-2024 | $-21.7M | $-19.07M | $4.35M | $635K | $-14.07M | $-19.09M |
CEO
Alexander C. Sapir
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 80
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Truist Securities
Buy
HC Wainwright & Co.
Buy
Leerink Partners
Outperform
Cantor Fitzgerald
Overweight
Piper Sandler
Overweight
RBC Capital
Sector Perform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:10.23M
Value:$105.97M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:5.38M
Value:$55.75M
TCG CROSSOVER MANAGEMENT, LLC
Shares:5.25M
Value:$54.39M
Summary
Showing Top 3 of 140